Showing 1 - 1 results of 1 for search 'Arvind Kinhikar', query time: 0.01s Refine Results
  1. 1
    Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial

    Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial by Martin Kaul, Peter End, Maciej Cabanski, Carole Schuhler, Annamaria Jakab, Magdalena Kistowska, Arvind Kinhikar, Alessio Maiolica, Angela Sinn, Rainard Fuhr, Bruno Cenni

    Published 2021
    Connect to this object online.
    Book
    Save to List
    Saved in:

Search Tools: